78 results
8-K
EX-99.2
NTRA
Natera, Inc.
8 Aug 24
Natera Reports Second Quarter 2024 Financial Results
4:11pm
Oncology. 2024. https://doi.org/10.1016/j.euo.2024.07.001 4. Shaw JA, Page K, Wren E, et al. Serial postoperative circulating tumor DNA assessment has
8-K
EX-99.2
NTRA
Natera, Inc.
9 May 24
Natera Reports First Quarter 2024 Financial Results
4:13pm
. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor - Derived Cell - Free DNA via Mass ively Multiplex PCR. J Clin Med. 2018;8(1 … ://doi.org/10.1016/j.ygyno.2023.12.025 2. Shaw JA, Page K, Wren E, et al. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic
8-K
EX-99.2
7ibrjbi
28 Feb 24
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
4:11pm
8-K
EX-99.2
0ggt31t
9 Jan 24
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
7:07am
424B5
qxl b5qtbzm
7 Sep 23
Prospectus supplement for primary offering
4:12pm
S-3ASR
wc0x4f9s818hb6sl
6 Sep 23
Automatic shelf registration
4:23pm
8-K
EX-99.2
r76uaph 7x6qt3870i9c
9 May 23
Natera Reports First Quarter 2023 Financial Results
4:01pm
POSASR
ehlxp8iu7j4v
6 Dec 22
Automatic shelf registration (post-effective amendment)
4:06pm
424B5
t7uj4 ejw3a2c6c52x4
16 Nov 22
Prospectus supplement for primary offering
4:59pm
S-3ASR
pzmsqh
15 Nov 22
Automatic shelf registration
4:16pm